WALTHAM,
Mass., Jan. 7, 2025 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of
Syndax, will present at the 43rd Annual J.P. Morgan Healthcare
Conference on Tuesday, January 14,
2025 at 10:30 a.m. PT/
1:30 p.m. ET.
A live webcast of the fireside chat can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the event will also be available for a limited
time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
Revuforj® (revumenib), an FDA-approved menin inhibitor, and
Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody
that blocks the colony stimulating factor 1 (CSF-1) receptor.
Fueled by our commitment to reimagining cancer care, Syndax is
working to unlock the full potential of its pipeline and is
conducting several clinical trials across the continuum of
treatment. For more information, please
visit www.syndax.com or follow the Company
on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-43rd-annual-jp-morgan-healthcare-conference-302343500.html
SOURCE Syndax Pharmaceuticals, Inc.